BioNTech guns for $250M raise at $4.5B valuation in IPO plan

BioNTech set the terms of its Nasdaq IPO. If BioNTech hits the midpoint of the range, it will raise $251 million (€228 million) at a $4.5 billion valuation, giving it the financial might to fund its broad clinical development pipeline.